World Health Organization and International Prognostic Scoring System: The Limitations of Current Classification Systems in Assessing Prognosis and Determining Appropriate Therapy in Myelodysplastic Syndromes

Seminars in Hematology

Volumn 45, Issue 1, 2008, Pages 3-7

  Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE CLASSIFICATION; DISEASE COURSE; FLOW CYTOMETRY; FOLLOW UP; HEALTH HAZARD; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REMISSION; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 37549028848     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.10.002     Document Type: Article

References (19)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
3. Haase D., Steidl C., Schanz J., Schabla R., Pfeilstöcker M., Nösslinger T., et al. Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS. Blood 106 suppl (2005) 787
4. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23 (2006) 7594-7603
5. Germing U., Hildebrandt B., Pfeilstocker M., Nosslinger T., Valent P., Fonatsch C., et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19 (2005) 2223-2231
6. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
7. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
8. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellström-Lindberg E. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
9. Germing U., Gattermann N., Strupp C., et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
10. Nosslinger T., Reisner R., Koller E., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood 98 (2001) 2935-2941
11. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
12. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. A randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
13. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006) 3895-3903
14. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
15. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
16. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
17. Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137 (2002) 156-163
18. Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., and Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100 (2002) 3639-3645
19. Valent H., Horny J., Bennett C., Fonatsch U., Germing P., Greenberg T., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31 (2007) 727-736